Join this workshop to explore the diverging pathways of drug development when T-Cell Engagers are applied to either lifethreatening malignancies or chronic autoimmune conditions.

• Analyzing the dual-target potential of CD38 to achieve deep plasma cell depletion and debating how the shift from oncology-level remission to autoimmune level long-term safety alters the risk benefit profile for chronic conditions
• Exploring alternative non-clinical models to prioritize immune restoration over cell depletion and debating the validity of NHP studies for predicting long-term tolerance
• Benchmarking MABEL-based dosing strategies in nonterminal patients and assessing computational modelling as a tool to bridge the gap between oncology’s toxicity-driven and autoimmunity’s safety-driven thresholds
• Evaluating the translational evidence required to justify the risk of chronic exposure and addressing the predictive limitations of traditional oncology safety packages for autoimmune use